Wearable Patches and Implantable Loop Recorders: The Impact of Continuous Rhythm Monitoring on Atrial Fibrillation Burden and Clinical Outcomes

Abstract

The diagnosis and management of atrial fibrillation are being fundamentally transformed by the advent of continuous rhythm monitoring technologies, namely wearable patches and implantable loop recorders. This evolution necessitates a comprehensive review of how these tools are reshaping our understanding of the atrial fibrillation disease spectrum and influencing clinical outcomes. A clear overview of the evidence is required to guide their effective and cost-efficient integration into clinical practice. This review first defines the core technologies of wearable patches and implantable loop recorders, comparing their distinct applications and limitations. It then explores the critical paradigm shift from detecting isolated atrial fibrillation episodes to quantifying atrial fibrillation burden, detailing its role as a key biomarker for stroke risk and disease progression. We examine the profound diagnostic impact of continuous monitoring in unmasking the cause of cryptogenic stroke, syncope, and palpitations, and its utility in screening high-risk populations. The discussion further analyzes how atrial fibrillation burden guides anticoagulation therapy beyond the CHA2DS2-VASc score and serves as a superior metric for assessing the efficacy of rhythm control therapies. Finally, the review considers the economic implications and healthcare system requirements for implementing these long-term monitoring strategies. Future efforts must focus on refining evidence-based, burden-driven thresholds for initiating anticoagulation and other interventions. Research and policy development should also prioritize optimizing patient selection and ensuring the cost-effective deployment of these monitoring tools across diverse healthcare settings. As technology advances, the integration of continuous rhythm data with other biomarkers promises to usher in an era of truly personalized, precision medicine for atrial fibrillation management.